Case Study: Approaches to Immunogenicity Risk Assessment of mRNA-LNP Products

Time: 9:00 am
day: Day One


  • Addressing specific regulatory guidelines for the identification and mitigation of unwanted immunogenicity risk factors for LNP-mRNA products
  • Defining a strategy utilizing a suite of in vitro immunogenicity/reactogenicity assays that could guide the immunogenicity de-risking by design of LNP-mRNA therapeutics